Stay updated with breaking news from Hematologic Malignancies Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PHILADELPHIA, Jan. 4, 2022 /PRNewswire/ -- Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia (B-ALL), rendering malignant cells resistant
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Credit: CincyTech Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 million Series A financing. The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors. "We are excited to have the support of exceptional investors. This financing allows us to expand our R&D program to substantially de-risk compound selection as we ident...
The company is developing multiple formulation candidates in its STAR-LLD program into non-clinical studies
- New clinical data highlight pelareorep's potential to boost the effectiveness of checkpoint inhibitors - Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments -